1. Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800.
2. Straube A, Andreou A. Primary headaches during lifespan. J Headache Pain. 2019;20(1):35.
3. Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, et al. Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2019;59(8):1286-99.
4. Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability. Headache. 2016;56(8):1280-9.
5. Dodick D, Edvinsson L, Makino T, Grisold W, Sakai F, Jensen R, et al. Vancouver Declaration on Global Headache Patient Advocacy 2018. Cephalalgia. 2018;38(13):1899-909.
6. Diener HC, Förderreuther S, Gaul C, Giese F, Hamann T, Holle-Lee D, et al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society. Neurological research and practice. 2020;2:11.
7. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644-55.
8. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nature reviews Neurology. 2018;14(6):338-50.
9. Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, et al. Erenumab Versus Topiramate for the Prevention of Migraine–A Randomised, Double-Blind, Active-Controlled Phase 4 Trial. Available at SSRN: https://ssrncom/abstract=3791424 or http://dxdoiorg/102139/ssrn3791424 2021(01.09.2021).
10. Schoenen J, Manise M, Nonis R, Gerard P, Timmermans G. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. Rev Neurol (Paris). 2020;176(10):788-803.
11. Sandor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache. 2000;40(1):30-5.
12. Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007;6(12):1054-62.
13. Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). J Headache Pain. 2019;20(1):60.
14. Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease. In: European Medicines Agency, editor. London: European Medicines Agency; 2018. p. 17-8.
15. Martelletti P. The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities. BioDrugs. 2017;31(6):483-5.
16. de Tommaso M, Ambrosini A, Brighina F, Coppola G, Perrotta A, Pierelli F, et al. Altered processing of sensory stimuli in patients with migraine. Nature reviews Neurology. 2014;10(3):144-55.
17. Lundblad C, Haanes KA, Grande G, Edvinsson L. Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. J Headache Pain. 2015;16:91.
18. Gantenbein AR, Agosti R, Gobbi C, Flugel D, Schankin CJ, Viceic D, et al. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia. 2021:3331024211014616.
19. Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019;20(1):66.
20. Ziegeler C, Mehnert J, Asmussen K, May A. Central effects of erenumab in migraine patients: An event-related functional imaging study. Neurology. 2020;95(20):e2794-e802.
21. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622.
22. Kaube H, Katsarava Z, Przywara S, Drepper J, Ellrich J, Diener HC. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology. 2002;58(8):1234-8.
23. Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P. Pathophysiological basis of migraine prophylaxis. Progress in neurobiology. 2009;89(2):176-92.
24. De Marinis M, Pujia A, Natale L, D'Arcangelo E, Accornero N. Decreased habituation of the R2 component of the blink reflex in migraine patients. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2003;114(5):889-93.
25. Olesen J. International Classification of Headache Disorders. Lancet Neurol. 2018;17(5):396-7.
26. Schoenen J. Is chronic migraine a never-ending migraine attack? Pain. 2011;152(2):239-40.
27. Magis D, Ambrosini A, Bendtsen L, Ertas M, Kaube H, Schoenen J, et al. Evaluation and proposal for optimalization of neurophysiological tests in migraine: part 1--electrophysiological tests. Cephalalgia. 2007;27(12):1323-38.
28. Ambrosini A, Magis D, Schoenen J. Migraine--clinical neurophysiology. Handb Clin Neurol. 2010;97:275-93.
29. Katsarava Z, Giffin N, Diener HC, Kaube H. Abnormal habituation of 'nociceptive' blink reflex in migraine--evidence for increased excitability of trigeminal nociception. Cephalalgia. 2003;23(8):814-9.
30. Giffin NJ, Kowacs F, Libri V, Williams P, Goadsby PJ, Kaube H. Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia. 2003;23(4):287-92.
31. Marx JJ. Die elektrophysiologische Untersuchung des Blinkreflexes. Klinische Neurophysiologie. 2003;34(01):8-14.
32. Oostenveld R, Fries P, Maris E, Schoffelen JM. FieldTrip: Open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data. Computational intelligence and neuroscience. 2011;2011:156869.
33. Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, et al. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clinical trials. 2012;9(3):322-9.
34. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior research methods. 2007;39(2):175-91.
35. de Tommaso M, Delussi M. Nociceptive blink reflex habituation biofeedback in migraine. Funct Neurol. 2017;32(3):123-30.
36. Artemenko AR, Kurenkov AL, Nikitin SS, Filatova EG. [Duloxetine in the treatment of chronic migraine]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):49-54.
37. Ayzenberg I, Obermann M, Nyhuis P, Gastpar M, Limmroth V, Diener HC, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia. 2006;26(9):1106-14.
38. Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 2016;139(Pt 7):1987-93.
39. de Tommaso M, Guido M, Libro G, Sciruicchio V, Puca F. Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans. Neuroscience letters. 2000;289(1):57-60.
40. Katsarava Z, Limmroth V, Baykal O, Akguen D, Diener HC, Kaube H. Differences of anti-nociceptive mechanisms of migraine drugs on the trigeminal pain processing during and outside acute migraine attacks. Cephalalgia. 2004;24(8):657-62.
41. Lapp HS, Sabatowski R, Weidner K, Croy I, Gossrau G. C-tactile touch perception in migraineurs - a case-control study. Cephalalgia. 2020;40(5):478-92.
42. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration (US). 2016.
43. Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, et al. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia. 2021;41(1):6-16.
44. Dresler T, Caratozzolo S, Guldolf K, Huhn JI, Loiacono C, Niiberg-Pikksoot T, et al. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain. 2019;20(1):51.